Search
What are you looking for?
Start main content

Press Releases

Press Releases

https://www.med.cuhk.edu.hk/press-releases/cuhk-pioneers-the-use-of-a-new-non-invasive-imaging-technology-to-measure-fatty-liver---a-problem-affecting-27-of-the-adult-population-in-hk
https://www.med.cuhk.edu.hk/press-releases/cuhk-pioneers-the-use-of-a-new-non-invasive-imaging-technology-to-measure-fatty-liver---a-problem-affecting-27-of-the-adult-population-in-hk

CUHK Pioneers the Use of a New Non-Invasive Imaging Technology to Measure Fatty Liver - a problem affecting 27% of the adult population in HK

It is estimated that 1 in 4 adults in Hong Kong suffers from nonalcoholic fatty liver disease (NAFLD), which is the most common liver disease worldwide. NAFLD is associated with metabolic syndrome and may progress to liver cirrhosis and liver cancer, affecting over half of the people with diabetes and obesity. The Center for Liver Health at The Chinese University of Hong Kong (CUHK) pioneers the use of a new non-invasive imaging technology-- Controlled Attenuation Parameter (CAP) to measure fatty liver. With early diagnosis and proper management, liver fat can be reversed and liver cancer can be prevented.

 

From left: Professor Vincent Wai Sun WONG, Professor, Division of Gastroenterology and Hepatology, Department of Medicine and Therapeutics and Deputy Director, Center for Liver Health at CUHK and Professor Grace Lai Hung WONG, Associate Professor, Department of Medicine and Therapeutics at CUHK present their recent research on the use of a new non-invasive imaging technology to identify mild fatty liver cases which may be missed by ultrasound scan

From left: Professor Vincent Wai Sun WONG, Professor, Division of Gastroenterology and Hepatology, Department of Medicine and Therapeutics and Deputy Director, Center for Liver Health at CUHK and Professor Grace Lai Hung WONG, Associate Professor, Department of Medicine and Therapeutics at CUHK present their recent research on the use of a new non-invasive imaging technology to identify mild fatty liver cases which may be missed by ultrasound scan.

Liver biopsy is the conventional test to assess liver fat and the severity of NAFLD. However, since it is an invasive test, many people prefer simple tests such as ultrasound and computed tomography (CT) scan, despite the limitations that ultrasound and CT scan can only pick up liver fat when more than 33% of the liver cells are fatty; and they cannot assess the severity of the disease.


Starting from 2010, Center for Liver Health pioneers the use of a non-invasive imaging technology, New Controlled Attenuation Parameter (CAP), to measure liver fat content. This novel tool is more sensitive than ultrasound scan, which can measure as low as 10% liver fat content and monitor the change of liver fat. The measurement is performed with a probe transducer placed on the skin surface over the right lobe of the liver. The process usually takes 5 minutes.

From 2010 to 2012, CUHK conducted a research on 238 patients who underwent liver biopsy and CAP assessment. 131 patients had fatty liver disease on histology. CAP was able to diagnose 120 patients (92%) with significant degree (>10%) of liver fat. 50 patients had liver fat between 10% and 33%. Compared to ultrasound scan, CAP was able to pick up these extra 38% (50 of 131) patients with significant liver fat. CAP also facilitated the early diagnosis of diabetes mellitus and liver cirrhosis. Among those fatty liver cases missed by ultrasound scan, 16 patients (32%) had diabetes mellitus and 8 patients (16%) had liver cirrhosis.

 

Professor Vincent Wai Sun WONG and Professor Grace Lai Hung WONG show the new non-invasive imaging technology—Controlled Attenuation Parameter

Professor Vincent Wai Sun WONG and Professor Grace Lai Hung WONG show the new non-invasive imaging technology—Controlled Attenuation Parameter.

In conclusion, CAP is an accurate, non-invasive assessment of liver fat. With this new tool, we are able to identify fatty liver disease which may be missed by ultrasound scan. Therefore, CUHK recommends the use of CAP as the screening test for fatty liver, particularly in patients with diabetes or obesity.

Members of the public who wish to take the CAP test can register via the 24-hour automated telephone system: 3151-5600 (Registration period: 19 Dec 2012 to 19 Jan 2013).

More Press Releases

CUHK Reveals Non-Alcoholic Fatty Liver Disease Afflicts Even the Non-Obese

CUHK Reveals Non-Alcoholic Fatty Liver Disease Afflicts Even the Non-Obese

Research
CUHK Develops Lifestyle Modification Program for Fatty Liver Patients 60% Patients Recovered Without Use of Drugs

CUHK Develops Lifestyle Modification Program for Fatty Liver Patients 60% Patients Recovered Without Use of Drugs

Health Campaign
CUHK-HCC Score Accurately Predicts Risk of Liver Cancer in Chronic Hepatitis B Patients Receiving Antiviral Therapy

CUHK-HCC Score Accurately Predicts Risk of Liver Cancer in Chronic Hepatitis B Patients Receiving Antiviral Therapy

Research
CUHK Estimates One Million Hong Kong People are Suffering from Fatty Liver Disease

CUHK Estimates One Million Hong Kong People are Suffering from Fatty Liver Disease

Research
CUHK Discovers High Prevalence of Colorectal Polyps among Fatty Liver Patients

CUHK Discovers High Prevalence of Colorectal Polyps among Fatty Liver Patients

Research
CUHK study reveals risk of liver-related complications but not liver cancer decreases over time in patients who have recovered from hepatitis B, regular cancer surveillance is recommended

CUHK study reveals risk of liver-related complications but not liver cancer decreases over time in patients who have recovered from hepatitis B, regular cancer surveillance is recommended

Research
CU Medicine Study Shows Liver Injury is Common and Prognostic in COVID-19 Patients

CU Medicine Study Shows Liver Injury is Common and Prognostic in COVID-19 Patients

Research
CUHK Discovers Fatty Liver Causing Severe Liver Fibrosis or Cirrhosis in 1 Out of 5 Diabetic Patients

CUHK Discovers Fatty Liver Causing Severe Liver Fibrosis or Cirrhosis in 1 Out of 5 Diabetic Patients

Research
CUHK Latest Research Reveals over 100,000 New Non-alcoholic Fatty Liver Cases in Hong Kong Annually

CUHK Latest Research Reveals over 100,000 New Non-alcoholic Fatty Liver Cases in Hong Kong Annually

Research
CUHK Survey: About 90% Hepatitis C Patients Unaware of Infection and Majority Refuses Treatment

CUHK Survey: About 90% Hepatitis C Patients Unaware of Infection and Majority Refuses Treatment

Research
Antiviral Therapy Can Prevent Liver Cancer Recurrence CUHK Represents HK to Draw Up Asian Pacific Treatment Guideline for Chronic Hepatitis B

Antiviral Therapy Can Prevent Liver Cancer Recurrence CUHK Represents HK to Draw Up Asian Pacific Treatment Guideline for Chronic Hepatitis B

Research
CUHK and French Researchers Pioneer the Use of Non-Invasive Imaging Technology – New XL Probe to Assess Liver Disease in Obese Patients

CUHK and French Researchers Pioneer the Use of Non-Invasive Imaging Technology – New XL Probe to Assess Liver Disease in Obese Patients

Research
CUHK Discovers the Use of Hepatitis B Surface Antigen Level as a New Marker for Disease Control in Chronic Hepatitis B Patients

CUHK Discovers the Use of Hepatitis B Surface Antigen Level as a New Marker for Disease Control in Chronic Hepatitis B Patients

Research
CU Medicine proves oral antivirals for COVID-19 can lower the risk of hospitalisation and  inpatient progression in older patients living in nursing homes

CU Medicine proves oral antivirals for COVID-19 can lower the risk of hospitalisation and inpatient progression in older patients living in nursing homes

Research
CUHK Discovers an Essential Oncogene in Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma

CUHK Discovers an Essential Oncogene in Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma

Research
CUHK Study Reveals Patients with Recovery of Hepatitis B Still at Risk of Liver Cancer

CUHK Study Reveals Patients with Recovery of Hepatitis B Still at Risk of Liver Cancer

Research
CUHK Assessed and Treated Over 300 Young Ketamine Abusers with Urinary Tract Dysfunction Latest Research Reveals Effectiveness of Integrated Anti-inflammatory Therapy

CUHK Assessed and Treated Over 300 Young Ketamine Abusers with Urinary Tract Dysfunction Latest Research Reveals Effectiveness of Integrated Anti-inflammatory Therapy

Research
CUHK Received Four Ministry of Education Higher Education Outstanding Scientific Research Output Awards The Highest Share among Hong Kong Institutions

CUHK Received Four Ministry of Education Higher Education Outstanding Scientific Research Output Awards The Highest Share among Hong Kong Institutions

Awards and honors

Our Expert List

Many experts under the Faculty of Medicine are available for media interview.
Please click here for the expert list or contact us.